Biotech companies are reaping the benefits of more accessible high-performance computing tools. The ability to compress weeks of modeling into days or hours is improving outcomes and boosting time to market.
DNA sequencing technology outruns genomic analysis.
Biotech firms require vast computational resources and for those smaller companies, this means maximizing current infrastructure and processes as much as possible. Bruce Maches weighs in one a recent implementation, looking at the challenges and possibilities for these companies.
It is not just big biotech companies that can leverage cloud computing; smaller early stage companies are also taking advantage of what cloud computing has to offer to cut costs, reduce complexity and ensure that resources are focused on the primary goals of the organization.
Continued advances in drug discovery will exponentially increase the amount of data generated during the discovery process. IT organizations or vendors that can supply the needed cloud-based infrastructure services in a secure and reliable manner will certainly do well in this space.
A chat with Paul Rejto, head of Computational Biology at Pfizer Oncology.
Amazon EC2 is still the platform of choice, but there are more clouds on the horizon.